Explore dementia care resources at The Bridge in Shreveport
The tours will allow guests to learn about The Bridge's programs, meet the team, and delve into its available services supporting caregivers and individuals living with Alzheimer's and other dementias in the region.
CHRISTUS highlights speech therapy for communication disorders
Guests will also be able to see The Bridge Adult Day Center, Northwest Louisiana's first dementia-centered adult day program. This program provides individuals with dementia with a safe, inviting environment while caregivers relax and refresh.
'We want people to know that they're not alone,' said Toni Goodin, Executive Director of The Bridge Alzheimer's & Dementia Resource Center. 'These tours are a simple way for anyone—whether a caregiver, family member, or healthcare provider—to come see what we offer and ask questions in a relaxed, welcoming setting.'
The first tour will take place on Tuesday, June 3, from 1:30 p.m. to 3:30 p.m. Registration is not required. For more information, visit The Bridge during tour hours.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
York firm raises £2 million to fuel growth
York-based life sciences company, Aptamer Group, has raised £2million from a placing of shares. Aptamer is a leading innovator in developing its Optimer® binder technology, which is being developed for a range of medical treatments. In the past year, the company reports strong commercial progress, winning a range of fee-for-service contracts. It has also extended its intellectual property portfolio. Several of these assets have progressed towards licensing, notably a swine vaccine and an Alzheimer's diagnostic, both of which are advancing to licensing agreements. RECOMMENDED READING: Aptamer Group reports progress on Fibrosis research Unilever signs up with Aptamer on body odour product trials Aptamer Group releases latest interim half yearly results Aptamer also reports further progress with its Optimer® delivery platform, being used for liver treatments. The share placing will enable Aptamer to accelerate the commercialisation of its Optimer® technology, further develop its intellectual property portfolio, and advance its licensing pipeline. The extra cash will also support ongoing R&D, expand fee-for-service capabilities, and strengthen the Company's position as a leader in the global aptamer market, driving long-term value creation for shareholders, it said.
Yahoo
4 hours ago
- Yahoo
Surprise Discovery About Sugar in The Brain Could Help Fight Alzheimer's
Stores of glucose in the brain could play a much more significant role in the pathological degeneration of neurons than scientists realized, opening the way to new treatments for conditions like Alzheimer's disease. Alzheimer's is a tauopathy; a condition characterized by harmful build-ups of tau proteins inside neurons. It's not clear, however, if these build-ups are a cause or a consequence of the disease. A new study now adds important detail by revealing significant interactions between tau and glucose in its stored form of glycogen. Led by a team from the Buck Institute for Research on Aging in the US, the research sheds new light on the functions of glycogen in the brain. Before now, it's only been regarded as an energy backup for the liver and the muscles. "This new study challenges that view, and it does so with striking implications," says molecular biologist Pankaj Kapahi, from the Buck Institute. "Stored glycogen doesn't just sit there in the brain, it is involved in pathology." Related: Building on links previously found between glycogen and neurodegeneration, the researchers spotted evidence of excessive glycogen levels both in tauopathy models created in fruit flies (Drosophila melanogaster) and in the brain cells of people with Alzheimer's. Further analysis revealed a key mechanism at play: tau proteins interrupt the normal breakdown and use of glycogen in the brain, adding to the dangerous build-up of both tau and glycogen, as well as lowering protective neuron defense barriers. Crucial to this interaction is the activity of glycogen phosphorylase or GlyP, the main enzyme tasked with turning glycogen into a fuel the body can use. When the researchers boosted GlyP production in fruit flies, glycogen stores were utilized once more, helping to fight back against cell damage. "By increasing GlyP activity, the brain cells could better detoxify harmful reactive oxygen species, thereby reducing damage and even extending the lifespan of tauopathy model flies," says Buck Institute biologist Sudipta Bar. The team wondered if a restricted diet – already associated with better brain health – would help. When fruit flies affected by tauopathy were put on a low-protein diet, they lived longer and showed reduced brain damage, suggesting that the metabolic shift prompted by dieting can help boost GlyP. It's a notable set of findings, not least because it suggests a way that glycogen and tau aggregation could be tackled in the brain. The researchers also developed a drug based around the 8-Br-cAMP molecule to mimic the effects of dietary restriction, which had similar effects on flies in experiments. The work might even tie into research involving GLP-1 receptor agonists such as Ozempic, designed to manage diabetes and reduce weight, but also now showing promise for protecting against dementia. That might be because these drugs interact with one of glycogen's pathways, the researchers suggest. "By discovering how neurons manage sugar, we may have unearthed a novel therapeutic strategy: one that targets the cell's inner chemistry to fight age-related decline," says Kapahi. "As we continue to age as a society, findings like these offer hope that better understanding – and perhaps rebalancing – our brain's hidden sugar code could unlock powerful tools for combating dementia." The research has been published in Nature Metabolism. Air Pollution 'Strongly Associated' With DNA Mutations Tied to Lung Cancer FDA Issues Warning Over Dangerous 'Gas Station Heroin' Substance Mysterious Leprosy Pathogen Has Lurked in The Americas For 4,000 Years
USA Today
8 hours ago
- USA Today
Dementia and Alzheimer's disease aren't the same thing. Here's why.
While dementia and Alzheimer's disease are terms that are often used interchangeably, they don't mean the same thing. Understanding the difference isn't just helpful for clarity, it's essential for making sense of symptoms, treatment options and what kind of care to hope for if you or a loved one receives either diagnosis. "While a diagnosis of Alzheimer's disease or dementia understandably brings fear and uncertainty, we are living in a time of unprecedented knowledge and more comprehensive care for patients than ever before," says Dr. Nathaniel Chin, medical director and clinical core co-leader of the Wisconsin Alzheimer's Disease Research Center at the University of Wisconsin-Madison. Here's what Alzheimer's disease is, what dementia is and how the two diagnoses differ. What is Alzheimer's disease? Alzheimer's disease is a progressive brain disorder that often begins years or even decades before symptoms appear. Eventually though, the abnormal biological processes occurring in the brain of someone with Alzheimer's will lead to the cognitive decline we associate with dementia, says Chin. "Alzheimer's disease is defined by two key proteins called beta-amyloid and tau," he explains. "Each builds up in the brain and leads to the death of brain cells, called neurodegeneration." When brain cells die, he adds, they can no longer communicate, "which is when people develop symptoms." Some of these symptoms include forgetfulness, difficulty finding words and struggles with reasoning, problem solving and judgment. 'Common signs include forgetting new information like recent conversations and having trouble coming up with common words and names,' says Jessica Caldwell, director of the Women's Alzheimer's Movement Prevention and Research Center at Cleveland Clinic. While some of these symptoms may be mild at first, Alzheimer's continues to damage the brain, which usually leads to more severe cognitive and functional decline. What is dementia? While Alzheimer's is a specific disease and the most common cause of dementia, dementia is a broader, "umbrella term that describes a collection of cognitive, functional and behavioral symptoms that are caused by a variety of specific diseases, Alzheimer's being one of them," explains Courtney Kloske, PhD, director of scientific engagement for the Alzheimer's Association. Other causes of dementia include vascular disease, frontotemporal degeneration, cerebrovascular disease, Parkinson's disease, Lewy body disease and even brain trauma. These different causes of dementia can present with varying symptoms and varying degrees of progression. Whether it's Alzheimer's disease or another cause, the symptoms of dementia typically include "short-term memory loss, repeating questions, misplacing items and struggling with everyday activities like managing medications, cooking and using technology,' says Chin. Eventually, dementia usually results in enough cognitive decline to "make it impossible for someone with it to function independently,' says Caldwell. Did you see? She had Parkinson's and didn't want to live. Then she got this surgery. What is the difference between dementia and Alzheimer's? Because Alzheimer's is just one of several diseases that cause dementia, the key distinction lies in their scope. 'Alzheimer's disease is a specific condition resulting from an abnormal biological process," explains Chin, "while dementia is a clinical syndrome.' One way to understand the difference: Dementia refers to the symptoms you see such as memory loss and confusion while Alzheimer's is causing those symptoms. 'Just like two people with cancer might have different types like skin cancer or breast cancer," says Caldwell, "two people with dementia might both have Alzheimer's, or one might have Alzheimer's while the other has a different condition entirely." One reason the terms are often used interchangeably is because Alzheimer's is the most common and most heavily researched form of dementia. And new treatments aimed at slowing its progression often bring it into the spotlight, sometimes blurring the lines between the terms in everyday use. Personal essay: Bruce Willis and my dad received the same aphasia diagnosis. Then everything changed. How are dementia and Alzheimer's disease treated? There's no cure for dementia nor Alzheimer's disease, but treatments are improving, with early detection and new medications offering patients and their families more reasons to hope. 'Both Alzheimer's and dementia are progressive and incurable,' says Chin, 'but Alzheimer's disease can now be identified in people without symptoms, sometimes as early as 20 years in advance.' Early detection allows patients and their families more time to access treatments, make plans and reduce uncertainty. Advancing treatments and new drugs are also helping. For example, the U.S. Food & Drug Administration has recently approved two new Alzheimer's medications: donanemab-azbt (brand name Kisunla), and lecanemab (brand name Leqembi). "These treatments have been shown to slow disease progression and reduce the rate of cognitive and functional decline," says Kloske. Additional research is continuing, care strategies are evolving and more people are being diagnosed earlier and earlier. "Getting diagnosed early," Caldwell says, "is the best way to have a chance to treat the disease, receive support and have a better quality of life."
